A gene therapy showing potential to restore lost developmental milestones in people living with Rett syndrome has earned breakthrough therapy status from the U.S. Food and Drug Administration (FDA). The experimental therapy, TSHA-102, is being developed by Taysha Gene Therapies. A breakthrough therapy designation is intended to speed the development and review of important new treatments for […] The post FDA grants breakthrough status to Rett syndrome treatment appeared first on Rett Synd...
